H.C. Wainwright Sticks to Their Buy Rating for Adicet Bio (ACET)

H.C. Wainwright analyst Edward White maintained a Buy rating on Adicet Bio (ACETResearch Report) today and set a price target of $35.00. The company’s shares closed last Thursday at $10.26.

According to, White has 0 stars on 0-5 stars ranking scale with an average return of -30.7% and a 18.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $29.00 average price target, a 179.9% upside from current levels. In a report issued on May 12, BTIG also maintained a Buy rating on the stock with a $34.00 price target.

See the top stocks recommended by analysts >>

Based on Adicet Bio’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $24.99 million and net profit of $4.62 million. In comparison, last year the company had a GAAP net loss of $21.32 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Read More on ACET:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More